Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Construction partner invests in Japan's UMN

This article was originally published in Scrip

Executive Summary

IHI Plant Engineering Corp (IPEC) has signed an agreement to assist the Japanese bioventure UMN Pharma to construct a ¥2 billion domestic production facility for a novel vaccine against the H5N1 strain of bird flu. As part of the tie-up, IPEC, an affiliate of Japan's Ishikawajima-Harima Heavy Industries group, is to acquire a roughly 2% stake in UMN for around ¥200 million ($1.8 million). The recombinant vaccine, UMN-0501, uses protein expression technology licensed from Protein Sciences and recently entered clinical trials in Japan, where it has orphan status (Scrip Online, June 11th, 2008). The planned manufacturing facility will have an initial annual capacity of 10 million doses.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts